Sarepta Boosts Elevidys Sales with FDA Expansion, Discontinues SRP-5051 Development

Sarepta Therapeutics has witnessed a significant boost in sales of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, following the FDA's expansion of its approved use. The third quarter saw Elevidys generating $181 million in revenue, which exceeded analysts' predictions and marked a 48% increase compared to previous quarters[1]. Originally sanctioned in June 2023 for ambulatory boys aged 4 and 5, the approval now encompasses all DMD patients age 4 and above, including non-ambulatory patients. This broader approval has significantly enhanced Elevidys's market reach, contributing to a notable rise in patient uptake and solidifying its strong sales performance[3]. Analysts anticipate sustained growth for Elevidys, noting the potential for further market penetration among those affected by DMD[1].